Article
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.
Lung cancer (Amsterdam, Netherlands) - 1 Nov 2025
van der Wel J W T, Ernst S M, Jebbink M, van den Broek D, Badrising S K, Steinbusch L C, Ruiter G, Theelen W S M E, van Veggel B A M H, Smit J, Dingemans A M, Paats M S, Dubbink H J, Hashemi S M S, Radonic T, Cohen D, van der Wekken A J, Ter Elst A, Timens W, Hendriks L E, Speel E J M, Disselhorst M M J, Welling A, van der Meer F, Bosch L J W, Monkhorst K, Boelens M C, Smit E F, de Langen A J
Abstract excerpt
BACKGROUND: Resistance mechanisms (RMs) inevitably develop during osimertinib treatment in EGFR mutation positive (EGFRm+) NSCLC, and may guide subsequent therapy. We hypothesized that a complete RM analysis requires next-generation sequencing (NGS) of tumor tissue and plasma in patients experiencing disease progression (PD) on first-line osimertinib. METHODS: At time of PD during osimertinib treatment, patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.